MFN

News

Advocacy group pokes holes in Trump's MFN pricing claims

Public Citizen says claims for the drug price savings that are being delivered by Trump's Most-Favoured Nation deals with pharma are "a mirage."

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

Market Access

Blue and white pills in pharma manufacturing line

Pharma’s most expensive question is the last one asked

Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.

News

White House signs pricing deals with nine more pharmas

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

Market Access

The new commercialisation playbook: What BIO 2026 taught eme...

BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.

News

MFN affecting Swiss medicines access, says Interpharma

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.

Advocacy group pokes holes in Trump's MFN pricing claims

Request to look further into NICE non-submissions in the fut...

Pharma’s most expensive question is the last one asked

White House signs pricing deals with nine more pharmas

The new commercialisation playbook: What BIO 2026 taught eme...

MFN affecting Swiss medicines access, says Interpharma

Novartis taps China's Abogen for autoimmunity TCE

Discover a new era of healthcare panel engagement: Grounded ...

MFN

Editor's Picks